Resources Repository
-
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Policy/Regulation | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global | North America -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Policy/Regulation | Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Government/Law | North America -
ArticlePublication 2020COVID-19 Infodemic: A New Front for Information Professionals
COVID-19 emerged from Wuhan, China and has spread in 213 countries, areas, or territories around …
COVID-19 emerged from Wuhan, China and has spread in 213 countries, areas, or territories around the globe, with nearly 144,683 deaths worldwide as-of April 18, 2020. In the wake of the COVID-19 pandemic, we have witnessed a massive infodemic with the public being bombarded with vast quantities of information, much of which is not scientifically correct. Fighting fake news is now the new front in the COVID-19 battle. This article comments on the role of…
Policy/Regulation | Preferences/Values | Infectious Diseases | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | Global -
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Policy/Regulation | Preferences/Values | Infectious Diseases | Social Determinants | Global Governance | Culture/Society | Health/Medicine | Science/Technology | Global -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Policy/Regulation | Probability/Bayes | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global | North America -
Resource PackPublication, Teaching Resource 2021Resource Pack: Valuing Health and Longevity in BCA
This resource pack, curated by the Center for Health Decision Science, introduces the valuation of …
This resource pack, curated by the Center for Health Decision Science, introduces the valuation of changes in health and longevity in benefit-cost analysis. It is targeted towards advanced students and practitioners who have a basic understanding of the benefit-cost analysis framework, as discussed in the Resource Pack: Introduction to Benefit-Cost Analysis. That pack provides a general overview of the approaches that are explored in more detail here, as well as related guidance documents. This pack…
Policy/Regulation | Preferences/Values | Benefit-Cost Analysis | College | Graduate | Critical Thinking/Analysis | Policy Translation -
Online LearningVideo, Teaching Resource 2020Valuing Statistical Lives: Concepts, Current Practices, and Challenges
Many policies aim to improve longevity, decreasing the risk of death in each year, and …
Many policies aim to improve longevity, decreasing the risk of death in each year, and the value of these risk reductions often dominate the estimated benefits of risk regulations and other policies. This value is often expressed as the value per statistical life (VSL), a term that is widely misunderstood. It is not the value that the analyst, the government, or the individual places on saving an identified life with certainty. Instead, it reflects individuals’…
Policy/Regulation | Benefit-Cost Analysis | Climate/Environment | Health/Medicine | Global -
ArticlePublication 2020Premature Deaths, Statistical Lives, and Years of Life
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of …
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of exposure to environmental hazards such as air pollution are often described by the estimated number of “premature deaths” and the economic value of an exposure reduction as the number of “statistical lives saved” multiplied by the “value per statistical life.” These terms can be misleading because the number of deaths advanced by exposure cannot be determined from mortality data; it…
Policy/Regulation | Preferences/Values | Health Outcomes | Benefit-Cost Analysis | Environmental Health | College | Graduate | Critical Thinking/Analysis